This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Source: OpenUrlAbstract/FREE Full Text
Investigators from multiple institutions in the Netherlands conducted a randomized controlled trial to determine the effect of intravenous immunoglobulin (IVIG) treatment for immune thrombocytopenia (ITP) on the development of chronic ITP. Children were eligible if they were 3 months to 16 years old, had newly diagnosed ITP, had a platelet count of ≤20 × 109/L, and had mild or moderate bleeding according to standardized bleeding score assessments. Participants were randomized to a treatment arm, in which they received a single dose (0.8 g/kg) of IVIG, or an observation arm, in which they were carefully observed and only received immunomodulatory treatment if they developed severe bleeding. Demographic and clinical data were collected at enrollment; data regarding symptoms, laboratory results, and clinical course were …
Individual Login
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.
Log in through your institution
Pay Per Article - You may access this article (from the computer you are currently using) for 2 days for US$25.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
In this issue
Related Articles
Cited By...
- No citing articles found.